Vergelijking

Survodutide vs. VK2735

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

2179963-22-7

geen gegevens

Molecuulmassa

4727 g/mol

geen gegevens

Halfwaardetijd

168 h

geen gegevens

Sequentie

modifiziertes 29-Aminosäuren-Peptid mit Fettsäureseitenkette

geen gegevens

Werkingsmechanisme

Survodutide

Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Survodutide	VK2735
Duitsland	Niet goedgekeurd	Niet goedgekeurd
JP	Niet goedgekeurd	—
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Survodutide

Volledige vermelding →

VK2735

Volledige vermelding →

Frequently asked questions

What is the difference between Survodutide and VK2735?: Survodutide is classified as "Metabool", while VK2735 is classified as "Metabool". Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Survodutide or VK2735?: The highest available evidence level is "Humane RCT" for Survodutide and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Survodutide and VK2735 in Germany and the United States?: Duitsland: Survodutide — Niet goedgekeurd, VK2735 — Niet goedgekeurd. Verenigde Staten: Survodutide — Niet goedgekeurd, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Survodutide

VK2735

Duitsland

Niet goedgekeurd

—

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Survodutide and VK2735?

Survodutide is classified as "Metabool", while VK2735 is classified as "Metabool". Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Survodutide or VK2735?

The highest available evidence level is "Humane RCT" for Survodutide and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Survodutide and VK2735 in Germany and the United States?

Duitsland: Survodutide — Niet goedgekeurd, VK2735 — Niet goedgekeurd. Verenigde Staten: Survodutide — Niet goedgekeurd, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.